Relevant bibliographies by topics / 004.415.2; 519.246.8

Contents

  1. Journal articles

Academic literature on the topic '004.415.2; 519.246.8'

Author: Grafiati
Published: 30 May 2022
Last updated: 31 May 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '004.415.2; 519.246.8.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "004.415.2; 519.246.8"

1

Xi, Jing, Kathleen Harnden, Jingqin Luo, et al. "Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations." Cancer Research 82, no. 4_Supplement (2022): P3–09–04—P3–09–04. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-09-04.

Full text
Abstract:
Abstract Background: Alpelisib and fulvestrant are used as a combination treatment option for postmenopausal PIK3CA-mutated, hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer (a/mBC) patients. However, despite the presence of activating mutations in PIK3CA, the majority of patients do not derive benefit, or ultimately progress while on alpelisib therapy. Here, we investigate the genomic landscape of PIK3CA-mutated, HER2- a/mBC using next-generation sequencing (NGS) to provide insight into possible mechanisms of ther
APA, Harvard, Vancouver, ISO, and other styles
2

Guglielmelli, Paola, Giada Rotunno, Annalisa Pacilli, et al. "Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients." Blood 126, no. 23 (2015): 351. http://dx.doi.org/10.1182/blood.v126.23.351.351.

Full text
Abstract:
Abstract Background. The prognostic significance of bone marrow (BM) fibrosis grade in pts with primary myelofibrosis (PMF) is debated. A fibrosis grade greater than 1 was associated with a 2-fold higher risk of death compared with pts with early/prefibrotic MF (grade 0) [Thiele J, Ann Hematol 2006]. Recent data suggest that more accurate prediction of survival is achieved when fibrosis grade is added to IPSS [Verner C, Blood 2008; Giannelli U, Mod Pathol 2012]. Aim. To analyze the prognostic impact of fibrosis in diagnostic BM samples of 540 WHO-2008 diagnosed PMF pts with extensive clinical
APA, Harvard, Vancouver, ISO, and other styles
3

Sorigue, Marc, Juan-Manuel Sancho, Santiago Mercadal, et al. "Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy." Blood 126, no. 23 (2015): 1510. http://dx.doi.org/10.1182/blood.v126.23.1510.1510.

Full text
Abstract:
Abstract Background: Follicular lymphoma (FL) is the most frequent indolent lymphoma and is characterized by a high response to immunochemotherapy (ICT). However, patients refractory to first-line ICT have a worse prognosis. The objective of this study was to determine the prevalence of refractory FL, the factors that predict refractoriness as well as the salvage treatment and outcome. Patients and methods: This is a retrospective analysis including stage II-IV FL patients treated with first-line ICT in 3 Spanish institutions. The cohort was divided into ICT-refractory patients (less than part
APA, Harvard, Vancouver, ISO, and other styles
4

Magnus, Dan, Santosh Bhatta, and Julie Mytton. "432 Establishing injury surveillance in emergency departments in Nepal: epidemiology and burden of paediatric injuries." Emergency Medicine Journal 37, no. 12 (2020): 825.2–827. http://dx.doi.org/10.1136/emj-2020-rcemabstracts.7.

Full text
Abstract:
Aims/Objectives/BackgroundGlobally, injuries cause more than 5 million deaths annually. Children and young people are a particularly vulnerable group and injuries are the leading cause of death in people aged 5–24 years globally and a leading cause of disability.In most low and middle-income countries where the majority of global child injury burden occurs, systems for routinely collecting injury data are limited. There is a continuing need for better data on childhood injuries and for injury surveillance.The aim of our study was to introduce a hospital-based injury surveillance tool – the fir
APA, Harvard, Vancouver, ISO, and other styles
5

Rivera Teran, V., D. Alpizar-Rodriguez, S. Sicsik, et al. "FRI0546 GENDER DIFFERENCES OF RHEUMATIC DISEASES IN MEXICAN POPULATION: DATA FROM THE MEXICAN BIOLOGICS REGISTRY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 874–75. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6091.

Full text
Abstract:
Background:Most autoimmune diseases are more prevalent in women. Symptom severity, disease progression, response to therapy and overall survival differ between males and females with rheumatic diseases.Objectives:To identify the characteristics of autoimmune diseases presentation and treatment between male and female population using information from the Mexican Adverse Events Registry (BIOBADAMEX).Methods:BIOBADAMEX is a Mexican ongoing cohort that collects the information of patients using biologic and biosimilar drugs since 2016. For this study we included all patients enrolled in the regis
APA, Harvard, Vancouver, ISO, and other styles
6

Sherrod, Amanda M., Nancy L. Wells, Mary S. Dietrich, and Barbara A. Murphy. "Examining caregiver perceptions and distress related to patient pain." Journal of Clinical Oncology 31, no. 15_suppl (2013): e20555-e20555. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20555.

Full text
Abstract:
e20555 Background: We conducted a randomized trial comparing a brief baseline pain educational intervention with the addition of either a hot line for pain related issues or weekly calls from health providers to assess pain and medication use. Results of this trial have been previously reported (J Pain Symptom Manage. 2003 Apr;25(4):344-56). Caregiver beliefs may impact patient compliance with pain treatment so caregivers also received pain education. As a secondary endpoint we investigated caregiver beliefs related to: 1) known barriers to compliance with pain medication (feasibility of pain
APA, Harvard, Vancouver, ISO, and other styles
7

Petrov, A. V., Y. O. Shevnina, A. S. Gaffarova, and A. A. Petrov. "Dynamic of radiographic and ultrasonographic indices of hip joints in patients with ankylosing spondylitis under treatment with tumor necrotic factor ― alpha inhibitors." Medical alphabet 2, no. 37 (2020): 54–58. http://dx.doi.org/10.33667/2078-5631-2019-2-37(412)-54-58.

Full text
Abstract:
Background. Inflammation of the hip joints in ankylosing spondylitis (AS) is a frequent and severe manifestation of the disease, which in 7–8 % of patients is accompanied by the requirements of hip joints prosthesis. In the treatment of hip arthritis associated with AS non-steroidal anti-inflammatory drugs (NSAIDs), sulfasalazine (SSZ) and tumor necrosis factor-alpha blockers were used. However, the influence of these treatment on the dynamics of structural changes in hip joints is not studied.Purpose. To evaluate the dynamics of clinical, radiologic and ultrasonographic indices of hip joints
APA, Harvard, Vancouver, ISO, and other styles
8

Swic, Sebastian J., Alexander G. T. MacPhail, Chinmay B. Dalal, et al. "Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database." Blood 124, no. 21 (2014): 2549. http://dx.doi.org/10.1182/blood.v124.21.2549.2549.

Full text
Abstract:
Abstract Background: Chronic Lymphocytic Leukemia (CLL) patients (pts) have significant (sig) heterogeneity; survival ranges from decades to <5 years (yrs). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is promising treatment (tx) for high-risk pts. Ideally, predictive (pred) tools would allow clinicians to recognize such pts early, permitting transplant performance to maximize benefit and minimize procedure associated risk. Factors with significant (sig) pred capacity are not, however, entirely clarified. Moreover, limited studies compare CLL pts who have/have not received
APA, Harvard, Vancouver, ISO, and other styles
9

Bassan, Renato, Arianna Masciulli, Tamara Intermesoli, et al. "Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL)." Blood 122, no. 21 (2013): 3901. http://dx.doi.org/10.1182/blood.v122.21.3901.3901.

Full text
Abstract:
Abstract Introduction Since the landmark study of Omura et al. (Blood 1980;55:199), validating cranial irradiation as an adjunct to intrathecal (IT) methotrexate, no other randomized trial of CNS prophylaxis was performed in adult ALL. Although the risk of CNS relapse is now only 1-4%, irradiation contributes to cumulative CNS toxicity together with high-dose methotrexate/cytarabine (HD-M/A), or is logistically difficult, so that developing an effective radiation-free CNS prophylaxis remains an important clinical task. IT DepoCyte® (ITD) might be advantageous, the slow release of liposome-asso
APA, Harvard, Vancouver, ISO, and other styles
10

Strati, Paolo, Kari Chaffee, Sara Achenbach, et al. "Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis." Blood 126, no. 23 (2015): 5265. http://dx.doi.org/10.1182/blood.v126.23.5265.5265.

Full text
Abstract:
Abstract Introduction. CLL primarily affects elderly individuals who frequently have comorbid health conditions. It is typically assumed non-CLL-related etiologies will be the ultimate cause of death for most CLL patients, particularly those with comorbid conditions at diagnosis. Methods. Between 9/2002 and 11/2014, 1174 patients with newly diagnosed CLL were enrolled in a prospective cohort study evaluating the natural history of CLL. Comorbidities were prospectively recorded at the time of diagnosis. Comorbidities arising during the course of disease were not considered for this analysis. St
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography